Arrowhead Research | ARWR - Fremdkapital

Aktienkurs
72.87
Täglich Wechseln
2.34 3.32%
Monatlich
16.22%
Jährlich
419.02%
Q2 Prognose
72.33




Fremdkapital Veränderung Datum
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Arrowhead Research USD 538.1M 323.22M 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
Merck USD 46.75B 6.78B 2025-12
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
TG Therapeutics USD 245.64M 305K 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03
Xencor USD 76.48M 11.29M 2025-12